

**Summary of Community Decisions on marketing authorisations in respect of medicinal products
from 15 February to 15 March 2002**

(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93 ⁽¹⁾)

(2002/C 77/06)

— Issuing of a marketing authorisation (Article 12 of Regulation (EEC) No 2309/93): Accepted

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
28.2.2002	Protopic	Fujisawa GmbH Levelingstraße 12 D-81673 München	EU/1/02/201/001-004	5.3.2002
28.2.2002	Protopy	Fujisawa GmbH Levelingstraße 12 D-81673 München	EU/1/02/202/001-004	5.3.2002
5.3.2002	Trisenox	Cell Therapeutics (UK) Limited 1 Ropemaker Street London EC2Y 9HT United Kingdom	EU/1/02/204/001	7.3.2002
8.3.2002	Lumigan	Allergan Pharmaceuticals (Ireland) Ltd Castlebar Road Westport County Mayo Ireland	EU/1/02/205/001	12.3.2002
8.3.2002	Kineret	Amgen Europe BV Minervum 7061 4817 ZK Breda Nederland	EU/1/02/203/001-004	12.3.2002

— Modification of a marketing authorisation (Article 12 of Regulation (EEC) No 2309/93): Accepted

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
5.2.2002	Cea-Scan	Immunomedics Europe Haarlemmerstraat 30 2181 HC Hillegom Nederland	EU/1/96/023/001	19.2.2002
19.2.2002	Renagel	Genzyme Europe BV Gooimeer 10 1411 DD Naarden Nederland	EU/1/99/123/001-011	22.2.2002
19.2.2002	Plavix	Sanofi Pharma Bristol-Myers Squibb SNC 174, avenue de France F-75013 Paris	EU/1/98/069/001a, 001b, 002a, 002b, 003a, 003b	21.2.2002
19.2.2002	Iscover	Bristol-Myers Squibb Pharma EEIG 141-149 Staines Road Hounslow TW3 3JA United Kingdom	EU/1/98/070/001a, 001b, 002a, 002b, 003a, 003b	22.2.2002

⁽¹⁾ OJ L 214, 24.8.1993, p. 1.

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
19.2.2002	Thyrogen	Genzyme BV Gooimeer 10 1411 DD Naarden Nederland	EU/1/99/122/001-002	22.2.2002
19.2.2002	SonoVue	Bracco International BV Strawinskylaan 3051 1077 ZX Amsterdam Nederland	EU/1/01/177/001-002	21.2.2002
19.2.2002	Caelyx	Schering Plough Europe Rue de Stalle/Stallestraat 73 B-1180 Brussels	EU/1/96/011/001-004	21.2.2002
19.2.2002	Teslascan	Amersham Health AS Nycoveien 1-2 PO Box 4220 Nydalen N-0401 Oslo	EU/1/97/040/001-002	25.2.2002
19.2.2002	Gonal F	Serono Europe Limited 56 Marsh Wall London E14 9TP United Kingdom	EU/1/95/001/017-020	21.2.2002
19.2.2002	Refludan	Schering AG D-13342 Berlin	EU/1/97/035/001-004	25.2.2002
19.2.2002	Vistide	Pharmacia Enterprises SA 6, Circuit de la Foire Internationale L-1347 Luxembourg	EU/1/97/037/001	22.2.2002
19.2.2002	Thyrogen	Genzyme Europe BV Gooimeer 10 1411 DD Naarden Nederland	EU/1/99/122/001-002	22.2.2002
19.2.2002	Prevenar	Wyeth-Lederle Vaccines SA Rue du Bosquet 15 B-1348 Louvain-La-Neuve	EU/1/00/167/001-005	12.3.2002
19.2.2002	Iscover	Bristol-Myers Squibb Pharma EEIG 141-149 Staines Road Hounslow TW3 3JA United Kingdom	EU/1/98/070/001a, 001b, 002a, 002b, 003a, 003b	22.2.2002
19.2.2002	Actos	Takeda Europe R & D Centre Ltd Savanah House 11/12 Charles II Street London SW1Y 4QU United Kingdom	EU/1/00/150/001-008	21.2.2002
19.2.2002	Mabthera	Roche Registration Limited 40 Broadwater Road Welwyn Garden City Hertfordshire AL7 3AY United Kingdom	EU/1/98/067/001-002	21.2.2002
19.2.2002	Karvezide	Bristol-Myers Squibb Pharma EEIG 141-149 Staines Road Hounslow TW3 3JA United Kingdom	EU/1/98/085/009-010	22.2.2002

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
19.2.2002	Arava	Aventis Pharma Deutschland GmbH D-65926 Frankfurt am Main	EU/1/99/118/005-008	25.2.2002
19.2.2002	Karvea	Bristol-Myers Squibb Pharma EEIG 141-149 Staines Road Hounslow TW3 3JA United Kingdom	EU/1/97/049/013-014	22.2.2002
19.2.2002	Arava	Aventis Pharma Deutschland GmbH D-65926 Frankfurt am Main	EU/1/99/118/001-010	25.2.2002
19.2.2002	Foscan	QuantaNova Limited Castle Business Park Stirling FK9 4TF United Kingdom	EU/1/01/197/001-002	21.2.2002
19.2.2002	Aprovel	Sanofi Pharma Bristol-Myers Squibb SNC 174, avenue de France F-75013 Paris	EU/1/97/046/014-015	25.2.2002
19.2.2002	Prevenar	Wyeth-Lederle Vaccines SA Rue du Bosquet 15 B-1348 Louvain-La-Neuve	EU/1/00/167/001-005	25.2.2002
19.2.2002	Neospect	Amersham Health AS Nycoveien 1-2 PO Box 4220 Nydalen N-0401 Oslo	EU/1/00/154/001-002	25.2.2002
19.2.2002	Coaprovel	Sanofi Pharma Bristol-Myers Squibb SNC 174, avenue de France F-75013 Paris	EU/1/98/086/009-010	25.2.2002
28.2.2002	Refacto	Genetics Institute of Europe BV Fraunhoferstraße 15 D-82152 Planegg/Martinsried	EU/1/99/103/001-003	5.3.2002
28.2.2002	Replagal	TKT Europe-5S AB Rinkebyvägen 11B S-182 36 Danderyd	EU/1/01/189/001	5.3.2002
28.2.2002	Vaniqa	Bristol-Myers Squibb Pharma EEIG 141-149 Staines Road Hounslow TW3 3JA United Kingdom	EU/1/01/173/001-003	5.3.2002
28.2.2002	Prevenar	Wyeth-Lederle Vaccines SA Rue du Bosquet 15 B-1348 Louvain-La-Neuve	EU/1/00/167/001-005	5.3.2002
5.3.2002	Viagra	Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ United Kingdom	EU/1/98/077/001-012	7.3.2002

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
5.3.2002	Patrex	Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ United Kingdom	EU/1/98/078/001-012	7.3.2002
5.3.2002	Prometax	Novartis Europharm Limited Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom	EU/1/98/092/001-013	7.3.2002
5.3.2002	Synagis	Abbott Laboratories Ltd Queenborough Kent ME11 5EL United-Kingdom	EU/1/99/117/001-002	7.3.2002
5.3.2002	Rilutek	Aventis Pharma SA 20, avenue Raymond-Aron F-92165 Antony Cedex	EU/1/96/010/001	7.3.2002
5.3.2002	Infergen	Yamanouchi Europe BV Elisabethhof 19 2353 EW Leiderdorp Nederland	EU/1/98/087/001-003	7.3.2002
7.3.2002	Fabrazyme	Genzyme Europe BV Gooimeer 10 1411 DD Naarden Nederland	EU/1/01/188/001-003	11.3.2002
8.3.2002	Avonex	Biogen France SA 55, avenue des Champs-Pierreux F-92012 Nanterre Cedex	EU/1/97/033/001-002	12.3.2002
8.3.2002	Aprovel	Sanofi Pharma Bristol-Myers Squibb SNC 174, avenue de France F-75013 Paris	EU/1/97/046/001-015	12.3.2002
8.3.2002	Karvea	Bristol-Myers Squibb Pharma EEIG 141-149 Staines Road Hounslow TW3 3JA United Kingdom	EU/1/97/049/001-015	12.3.2002
8.3.2002	Karvezide	Bristol-Myers Squibb Pharma EEIG 141-149 Staines Road Hounslow TW3 3JA United Kingdom	EU/1/98/085/001-010	12.3.2002
8.3.2002	Puregon	Organon NV Postbus 20 5340 BH Oss Nederland	EU/1/96/008/001-039	12.3.2002
8.3.2002	Coaprovel	Sanofi Pharma Bristol-Myers Squibb SNC 174, avenue de France F-75013 Paris	EU/1/98/086/001-010	12.3.2002

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
13.3.2002	Exelon	Novartis Europharm Limited Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom	EU/1/98/066/001-013	15.3.2002
14.3.2002	Travatan	Alcon Laboratories (UK) Ltd Boundary Way Hemel Hempstead Herts HP2 7UK United Kingdom	EU/1/01/199/001-002	18.3.2002

— Issuing of a marketing authorisation (Article 34 of Regulation (EEC) No 2309/93): Accepted

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
8.3.2002	Eurifel RCP FelV	Merial 17, rue Bourgelat F-69002 Lyon	EU/2/02/031/001-002	12.3.2002

— Modification of a marketing authorisation (Article 34 of Regulation (EEC) No 2309/93): Accepted

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
13.3.2002	Metacam	Boehringer Ingelheim Vetmedica GmbH D-55216 Ingelheim am Rhein	EU/2/97/004/003-005	15.3.2002

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

The European Agency for the Evaluation of Medicinal Products
7 Westferry Circus
Canary Wharf
London E14 4HB
United Kingdom.